Another phase 1 clinical trial administered CAR-EFGRvIII after lymphodepleting chemotherapy with intravenous interleukin-2 (IL-2) to 18 patients with recurrent GBM expressing EGFRvIII. This evidence concerns the gene IL2 and glioblastoma.